CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Analyst Earnings Estimates
NASDAQ:CNTA - Nasdaq - US1523091007 - ADR - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.853M | -100.00% | 3.213M | -100.00% | 136.92M | 444.96M 224.98% | 781.44M 75.62% | 1.155B 47.80% | 1.519B 31.52% | ||||
| EBITDA YoY % growth | -153.6M -1,371.26% | -212.13M -38.11% | -170.473M 19.64% | -173.483M -1.77% | -239.402M -38.00% | -285.531M -19.27% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -153.63M -1,371.55% | -212.26M -38.16% | -171.283M 19.31% | -178.93M -4.46% | -204.967M -14.55% | -238.964M -16.59% | -261.273M -9.34% | -167.28M 35.98% | 79.229M 147.36% | 357.46M 351.17% | 678.5M 89.81% | 1.01B 48.86% | |
| Operating Margin | N/A | N/A | -2,499.39% | N/A | N/A | -7,437.40% | N/A | -122.17% | 17.81% | 45.74% | 58.74% | 66.49% | |
| EPS YoY % growth | N/A | -2.31 -11.38% | -1.57 32.03% | -1.55 1.06% | -1.59 -2.68% | -1.68 -5.58% | -2.22 -32.04% | -1.53 31.19% | -0.56 63.33% | 1.02 281.82% | 3.01 195.00% | 4.90 62.71% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.41 -7.10% | -0.42 -10.72% | -0.45 -11.56% | -0.44 -19.92% | -0.43 -6.10% |
| Revenue Q2Q % growth | -100.00% | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -49.001M -39.29% | -52.081M -44.31% | -55.317M -25.78% | -57.992M -18.36% | -59.534M -21.50% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.37 7.50% | -0.42 | 0.05 | 12.70% |
| Q2 2024 Q2Q % growth | -0.40 -53.85% | -0.39 | -0.01 | -1.54% |
| Q1 2024 Q2Q % growth | -0.38 28.30% | -0.43 | 0.05 | 12.00% |
| Q4 2023 Q2Q % growth | -0.38 15.56% | -0.49 | 0.11 | 22.59% |
| Q3 2023 Q2Q % growth | -0.40 29.82% | -0.53 | 0.13 | 23.96% |
| Q2 2023 Q2Q % growth | -0.26 62.32% | -0.50 | 0.24 | 48.23% |
| Q1 2023 Q2Q % growth | -0.53 11.67% | -0.42 | -0.11 | -25.91% |
| Q4 2022 Q2Q % growth | -0.45 33.82% | -0.49 | 0.04 | 8.28% |
| Q3 2022 Q2Q % growth | -0.57 -26.67% | -0.58 | 0.01 | 1.09% |
| Q2 2022 Q2Q % growth | -0.69 -6.15% | -0.58 | -0.11 | -18.68% |
| Q1 2022 Q2Q % growth | -0.60 19.42% | -0.71 | 0.11 | 15.56% |
| Q4 2021 Q2Q % growth | -0.68 | -0.61 | -0.07 | -11.73% |
| Q3 2021 Q2Q % growth | -0.45 | -0.56 | 0.11 | 20.27% |
| Q2 2021 Q2Q % growth | -0.65 | -0.68 | 0.03 | 4.17% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0.9% | 7.64% |
| Revenue | N/A | N/A | N/A | N/A |